Aprea Therapeutics Stock Is Trading Higher As Eprenetapopt Triplet Therapy Achieves 37% CR Rate In Leukemia Patients

Aprea Therapeutics Inc APRE has announced that the Phase 1/2 trial evaluating eprenetapopt in acute myeloid leukemia (AML) has met the pre-specified primary efficacy endpoint of complete remission (CR) rate.
The trial is assessing eprenetapopt with venetoclax and azacitidine in patients with TP53 mutant AML.
In 30 patients who were evaluable for efficacy at the time of the analysis, the CR rate was 37%.
The composite rate of CR plus CR with incomplete hematologic recovery (CRi), CR/CRi, was 53%.
Eleven patients remain on study treatment and continue to be followed for safety and efficacy as of the data cut.
The Company plans to discuss the dataset with the FDA in the second half of 2021.
Data from the trial will be presented at a future scientific or medical conference.
Price Action: APRE shares are up 49.7% at $7.26 during the premarket session on the last check Wednesday.